Small extracellular vesicles obtained from hypoxic mesenchymal stromal cells have unique characteristics that promote cerebral angiogenesis, brain remodeling and neurological recovery after focal cerebral ischemia in mice

Jonas Gregorius1 · Chen Wang1 · Oumaima Stambouli2 · Tanja Hussner1 · Yachao Qi1 · Tobias Tertel2 · Verena Börger2 · Ayan Mohamud Yusuf1 · Nina Hagemann1 · Dongpei Yin1 · Robin Dittrich2 · Yanis Mouloud2 · Fabian D. Mairinger3 · Fouzi El Magraoui4 · Aurel Popa-Wagner5 · Christoph Kleinschnitt1 · Thorsten R. Döppner6 · Matthias Gunzer4,7 · Helmut E. Meyer4,8 · Bernd Giebel2 · Dirk M. Hermann1

Received: 17 December 2020 / Accepted: 18 May 2021 / Published online: 8 June 2021
© The Author(s) 2021, corrected publication 2021

Abstract

Obtained from the right cell-type, mesenchymal stromal cell (MSC)-derived small extracellular vesicles (sEVs) promote stroke recovery. Within this process, microvascular remodeling plays a central role. Herein, we evaluated the effects of MSC-sEVs on the proliferation, migration, and tube formation of human cerebral microvascular endothelial cells (hCMEC/D3) in vitro and on post-ischemic angiogenesis, brain remodeling and neurological recovery after middle cerebral artery occlusion (MCAO) in mice. In vitro, sEVs obtained from hypoxic (1% O2), but not ‘normoxic’ (21% O2) MSCs dose-dependently promoted endothelial proliferation, migration, and tube formation and increased post-ischemic endothelial survival. sEVs from hypoxic MSCs regulated a distinct set of miRNAs in hCMEC/D3 cells previously linked to angiogenesis, three being upregulated (miR-126-3p, miR-140-5p, let-7c-5p) and three downregulated (miR-186-5p, miR-370-3p, miR-409-3p). LC/MS–MS revealed 52 proteins differentially abundant in sEVs from hypoxic and ‘normoxic’ MSCs. 19 proteins were enriched (among them proteins involved in extracellular matrix–receptor interaction, focal adhesion, leukocyte transendothelial migration, protein digestion, and absorption), and 33 proteins reduced (among them proteins associated with metabolic pathways, extracellular matrix–receptor interaction, focal adhesion, and actin cytoskeleton) in hypoxic MSC-sEVs. Post-MCAO, sEVs from hypoxic MSCs increased microvascular length and branching point density in previously ischemic tissue assessed by 3D light sheet microscopy over up to 56 days, reduced delayed neuronal degeneration and brain atrophy, and enhanced neurological recovery. sEV-induced angiogenesis in vivo depended on the presence of polymorphonuclear neutrophils. In neutrophil-depleted mice, MSC-sEVs did not influence microvascular remodeling. sEVs from hypoxic MSCs have distinct angiogenic properties. Hypoxic preconditioning enhances the restorative effects of MSC-sEVs.

Keywords Endothelial migration · Microvascular network characteristics · Microvascular remodeling · Neuronal survival · Polymorphonuclear neutrophil · Tube formation

Introduction

Small extracellular vesicles (sEVs), such as exosomes (50–150 nm), play important roles in intercellular communication [37]. In response to injury, sEVs can promote restorative processes [39]. sEVs prepared from mesenchymal stromal cell (MSC) supernatants have been shown to promote neurological recovery and brain remodeling after focal cerebral ischemia in rats and mice [7, 30, 35, 36]. sEVs possess important characteristics which make them

Jonas Gregorius and Chen Wang have equally contributed to this work.

* Bernd Giebel
  bernd.giebel@uk-essen.de

* Dirk M. Hermann
  dirk.hermann@uk-essen.de

Extended author information available on the last page of the article
The effects of MSC-sEVs on cerebral microvascular angiogenesis in an hypoxia-inducible factor-1α (HIF-1α) dependent way cultured human umbilical vein endothelial cells (HUVECs) reported to increase the proliferation and tube formation of and tumor microenvironment [6, 18, 41], MSC-sEV preparations may promote or inhibit angiogenesis depending on the precise MSC source. While MSC-sEVs were previously found in the ischemic brain after MSC-sEV delivery in mice [7]. sEV-induced neuroprotection went along with restorative capacity of MSCs. Hypoxia did not result in any histological signs of structural MSC cell injury. Hypoxia did not influence MSC viability assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). As MSC culture medium, Dulbecco’s Modified Eagle’s Medium was used containing low glucose (DMEM low glucose, Lonza, Basel, Switzerland) supplemented with 10% platelet lysate obtained from pooled healthy donors (Institute of Transfusion Medicine, University Hospital Essen), 100 U/ml penicillin/streptomycin/glutamine (Gibco/Life Technologies, Carlsbad, CA, USA) and 5 IU/ml heparin (ratiopharm, Ulm, Germany). sEVs were isolated utilizing an optimized ultracentrifugation as described before [3, 21]. Three independent preparations of 41.5 MSC-sEVs were performed under ‘normoxic’ (21% O₂; sEVnormoxic) and hypoxic (1% O₂; sEVhypoxic) conditions over 48 h. Hypoxic preconditioning was used to mimic the effects of stroke-associated hypoxia on the restorative capacity of MSCs. Hypoxia did not result in any histological signs of structural MSC cell injury. Hypoxia did not influence MSC viability assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). As MSC culture medium, Dulbecco’s Modified Eagle’s Medium was used containing low glucose (DMEM low glucose, Lonza, Basel, Switzerland) supplemented with 10% platelet lysate obtained from pooled healthy donors (Institute of Transfusion Medicine, University Hospital Essen), 100 U/ml penicillin/streptomycin/glutamine (Gibco/Life Technologies, Carlsbad, CA, USA) and 5 IU/ml heparin (ratiopharm, Ulm, Germany). sEVs were isolated utilizing an optimized polyethylene glycol 6000 precipitation protocol followed by ultracentrifugation as described before [3, 21]. Three independent preparations of 41.5 MSC-sEVs were performed under ‘normoxic’ (21% O₂; sEVnormoxic) and hypoxic (1% O₂; sEVhypoxic) conditions, which were each evaluated in proliferation, transwell migration, and tube formation assays. All MSC-sEV preparations were characterized according to

Materials and methods

Propagation, isolation and characterization of MSCs and MSC-sEVs

Following previously described protocols [17, 25], we raised MSCs from bone marrow samples of seven randomly selected healthy human donors (MSC sources 41.5, 16.3, 117.3, 126.7, 142.1, 152.6, 153.3), some of which (sources 41.5, 16.3) have previously been characterized by us in an in vivo intraluminal MCAO model in the acute stroke phase [30]. These cells exhibit bona fide MSC characteristics, expressing cell surface antigens CD44, CD73, CD90 and CD105 and lacking endothelial and hematopoietic marker proteins (that is, CD31, CD34 and CD45) (Suppl. Fig. 1). The cells have proven differentiation capacity in osteogenic and adipogenic lineages [30]. sEVs were obtained from supernatants, while MSCs were cultured under regular ‘normoxic’ (21% O₂; sEVnormoxic) or hypoxic (1% O₂; sEVhypoxic) conditions. sEVs were abolished by PMN depletion, indicating that PMNs support the restorative effects of MSC-sEVs in the post-acute stroke phase.

The effects of MSC-sEVs on microvessels strongly depend on tissues and pathophysiological states. While MSC-sEV preparations may promote or inhibit angiogenesis in cancer tissues depending on the precise MSC source and tumor microenvironment [6, 18, 41], MSC-sEVs were reported to increase the proliferation and tube formation of cultured human umbilical vein endothelial cells (HUVECs) in an hypoxia-inducible factor-1α (HIF-1α) dependent way [9]. The effects of MSC-sEVs on cerebral microvascular angiogenesis were so far not systematically examined. To evaluate the effects of MSC-sEVs on cerebral angiogenesis, we herein exposed human microvascular endothelial cells (hCMEC/D3) to sEV preparations obtained from MSCs of two randomly selected healthy human donors, which had been cultured under regular ‘normoxic’ conditions (21% O₂) or hypoxic conditions (1% O₂), or to sEVs obtained from MSC culture media, which contain platelet lysates. In additional studies, mice that underwent intraluminal MCAO likewise received sEV preparations from ‘normoxic’ MSCs, from hypoxic MSCs or from cell culture media. In some subgroups, polymorphonuclear neutrophil leukocytes (PMN), which have previously been shown to mediate acute neuroprotective effects of MSC-sEVs [30], were depleted. We report that sEVs obtained from hypoxic, but not ‘normoxic’ MSCs or culture media induce angiogenesis as indicated by endothelial proliferation, transwell migration or tube formation assays in vitro and microvascular network characteristic analysis in vivo. Interestingly, sEVs from hypoxic MSCs regulated a distinct set of hitherto unrecognized miRNAs in hCMEC/D3 cells that have been linked to angiogenesis. Liquid chromatography/tandem mass spectrometry (LC/MS–MS) revealed previously unnoted proteins in sEVs from hypoxic MSCs that mediate their angiogenic properties. In vivo, the proangiogenic effects of hypoxic MSC-sEVs were abolished by PMN depletion, indicating that PMNs support the restorative effects of MSC-sEVs in the post-acute stroke phase.

attractive as therapeutics. In contrast to cell therapies, sEVs are not self-replicating and they lack endogenous tumor formation potentials [19]. sEVs can hardly sense environmental conditions, and thus, their biological activity can be predicted more reliably than that of cells [19]. Due to their small size, sEV products can be sterilized by filtration. Hence, their handling is much easier than that of cells. Due to these promising features, sEVs are rapidly approaching clinical trials in human patients [19].

In a head-to-head study in mice, we have previously demonstrated that sEV preparations obtained from supernatants of MSCs cultured under regular, that is, ‘normoxic’, conditions (21% O₂) equally effectively reduced motor-coordination deficits and increased long-term neuronal survival as their parental MSCs, when they were intravenously administered 24 h after intraluminal middle cerebral artery occlusion (MCAO) [7]. sEV-induced neuroprotection went along with sustained neurogenesis [7]. Neurogenesis and angiogenesis are tightly linked in the ischemic brain [14] and both processes closely accompany successful brain remodeling [12]. Since the cerebral microvasculature, namely endothelial cells, are exposed to intravenously delivered sEVs as first-line targets, the induction of angiogenesis may be instrumental for the capacity of MSC-sEVs to protect ischemic brain tissue. Indeed, evidence of endothelial proliferation was previously found in the ischemic brain after MSC-sEV delivery in mice [7].

The effects of MSC-sEVs on microvessels strongly depend on tissues and pathophysiological states. While MSC-sEV preparations may promote or inhibit angiogenesis in cancer tissues depending on the precise MSC source and tumor microenvironment [6, 18, 41], MSC-sEVs were reported to increase the proliferation and tube formation of cultured human umbilical vein endothelial cells (HUVECs) in an hypoxia-inducible factor-1α (HIF-1α) dependent way [9]. The effects of MSC-sEVs on cerebral microvascular angiogenesis were so far not systematically examined. To evaluate the effects of MSC-sEVs on cerebral angiogenesis, we herein exposed human microvascular endothelial cells (hCMEC/D3) to sEV preparations obtained from MSCs of two randomly selected healthy human donors, which had been cultured under regular ‘normoxic’ conditions (21% O₂) or hypoxic conditions (1% O₂), or to sEVs obtained from MSC culture media, which contain platelet lysates. In additional studies, mice that underwent intraluminal MCAO likewise received sEV preparations from ‘normoxic’ MSCs, from hypoxic MSCs or from cell culture media. In some subgroups, polymorphonuclear neutrophil leukocytes (PMN), which have previously been shown to mediate acute neuroprotective effects of MSC-sEVs [30], were depleted. We report that sEVs obtained from hypoxic, but not ‘normoxic’ MSCs or culture media induce angiogenesis as indicated by endothelial proliferation, transwell migration or tube formation assays in vitro and microvascular network characteristic analysis in vivo. Interestingly, sEVs from hypoxic MSCs regulated a distinct set of hitherto unrecognized miRNAs in hCMEC/D3 cells that have been linked to angiogenesis. Liquid chromatography/tandem mass spectrometry (LC/MS–MS) revealed previously unnoted proteins in sEVs from hypoxic MSCs that mediate their angiogenic properties. In vivo, the proangiogenic effects of hypoxic MSC-sEVs were abolished by PMN depletion, indicating that PMNs support the restorative effects of MSC-sEVs in the post-acute stroke phase.

Materials and methods

Propagation, isolation and characterization of MSCs and MSC-sEVs

Following previously described protocols [17, 25], we raised MSCs from bone marrow samples of seven randomly selected healthy human donors (MSC sources 41.5, 16.3, 117.3, 126.7, 142.1, 152.6, 153.3), some of which (sources 41.5, 16.3) have previously been characterized by us in an in vivo intraluminal MCAO model in the acute stroke phase [30]. These cells exhibit bona fide MSC characteristics, expressing cell surface antigens CD44, CD73, CD90 and CD105 and lacking endothelial and hematopoietic marker proteins (that is, CD31, CD34 and CD45) (Suppl. Fig. 1). The cells have proven differentiation capacity in osteogenic and adipogenic lineages [30]. sEVs were obtained from supernatants, while MSCs were cultured under regular ‘normoxic’ (21% O₂; sEVnormoxic) or hypoxic (1% O₂; sEVhypoxic) conditions over 48 h. Hypoxic preconditioning was used to mimic the effects of stroke-associated hypoxia on the restorative capacity of MSCs. Hypoxia did not result in any histological signs of structural MSC cell injury. Hypoxia did not influence MSC viability assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). As MSC culture medium, Dulbecco’s Modified Eagle’s Medium was used containing low glucose (DMEM low glucose, Lonza, Basel, Switzerland) supplemented with 10% platelet lysate obtained from pooled healthy donors (Institute of Transfusion Medicine, University Hospital Essen), 100 U/ml penicillin/streptomycin/glutamine (Gibco/Life Technologies, Carlsbad, CA, USA) and 5 IU/ml heparin (ratiopharm, Ulm, Germany). sEVs were isolated utilizing an optimized polyethylene glycol 6000 precipitation protocol followed by ultracentrifugation as described before [3, 21]. Three independent preparations of 41.5 MSC-sEVs were performed under ‘normoxic’ (21% O₂; sEVnormoxic) and hypoxic (1% O₂; sEVhypoxic) conditions, which were each evaluated in proliferation, transwell migration, and tube formation assays. All MSC-sEV preparations were characterized according to
the current minimal recommendations of the International Society of Extracellular Vesicles (ISEV) [25]. Particle concentration and size of sEV preparations were analyzed using nanoparticle tracking analysis (Suppl. Table 1). Protein contents of sEVs were determined using the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL, USA) (Suppl. Table 1). Using Western blots, we had previously shown the presence of the exosome markers CD9, CD63, CD81, and syntenin and the absence of the cytosolic markers calnexin and prohibitin in our sEV preparations [30]. By imaging flow cytometry (IFC) using the AMNIS ImageStreamX Mark II Flow Cytometer (Luminex, Seattle, WA, USA), we now showed that the number of CD9+, CD63+ and CD81+sEVs varied in different sEV preparations from the same source, independent of whether sEVs were collected under ‘normoxic’ or hypoxic conditions (Suppl. Fig. 2). For staining, anti-CD9 (EXBIO, Vestec, Czech Republic), anti-CD63 (EXBIO), and anti-CD81 (Beckman Coulter, Brea, CA, USA) or corresponding isotype antibodies were used [10, 28]. Transmission electron microscopy confirmed the presence of CD9+sEVs that had the appearance (double membrane-like configuration) and size (50–160 nm diameter) of exosomes (Suppl. Fig. 3). Data were analyzed as described previously using IDEAS software (version 6.2).

**Endothelial cell culture**

hCMEC/D3 cells (kindly provided by Dr. Pierre-Olivier Couraud, Paris) from passage 28 to 34 were cultivated in Endothelial Cell Growth Basal Medium-2 (EBM-2; Lonza) containing 5% fetal bovine serum (FBS) (Gibco/Life Technologies), 1% Hepes buffer (10 mM, Gibco/Life Technologies), 1% chemically defined lipid concentrate (Gibco/Life Technologies), 1% penicillin/streptomycin solution (Gibco/Life Technologies), 0.5% ascorbic acid (5 µg/mL), 0.5% human basic fibroblast growth factor (bFGF; 1 ng/mL; Sigma-Aldrich, St. Louis, MO, USA), and 0.05% hydrocortisone (1.4 µM, Sigma-Aldrich) in a humidified atmosphere at 37 °C containing 21% O₂ and 5% CO₂.

**Proliferation assay**

Samples of 3 × 10⁵ hCMEC/D3 cells were seeded in 6-well plates containing EBM-2 medium complemented with 1.25% FBS (other supplements as above). sEVs at various concentrations (0–250 µg/mL) obtained from (a) MSC culture medium (DMEM low, Lonza) supplemented with 10% platelet lysate (sEVplatelet), (b) supernatants of MSCs cultured under regular ‘normoxic’ conditions (21% O₂; sEVnormoxic), or (c) supernatants of MSCs cultured under hypoxic conditions (1% O₂; sEVhypoxic) were added. Forty-eight hours later, cells were stained with 0.4% trypan blue (Sigma-Aldrich). The number of viable cells was determined using an automatic cell counter (EVE Automatic Cell Counter; NanoEnTek, Waltham, MA, USA).

**Transwell migration assay**

Similarly, 3 × 10⁴ hCMEC/D3 cells were seeded into the upper compartment of polycarbonate membrane transwell inserts (8.0 µm pores; GE Healthcare Life Sciences, Chicago, IL, USA) in 24-well plates containing EBM-2 medium complemented with 1.25% FBS (other supplements as above). (a) sEVplatelet, (b) sEVnormoxic or (c) sEVhypoxic (as above) at various concentrations (0–250 µg/mL) were added into the lower compartment. Twenty-four hours later, remaining cells on top of the filter were removed with 0.1 M phosphate-buffered saline (PBS; Gibco/Life Technologies) soaked cotton swabs and cells that crossed the filter were fixed with 4% PFA followed by Hoechst staining. For image acquisition, filters were cut and mounted on glass slides using Fluoromount medium (Thermo Fisher Scientific, Waltham, MA, USA). Images were taken at 20X magnification using a fluorescence microscope (BX51, Olympus, Shinjuku, Japan). The number of migrated cells was counted using ImageJ software (National Institutes of Health, Bethesda, MD, USA) in a total of 7 regions of interest (ROI) per filter measuring 600 × 400 µm.

**Tube formation assay**

Likewise, 3 × 10⁴ hCMEC/D3 cells were seeded in 96-well plates precoated with Matrigel (Corning, Corning, NY, USA). (a) sEVplatelet, (b) sEVnormoxic or (c) sEVhypoxic (as above) at various concentrations (0–250 µg/mL) were added. Twenty hours later, images were taken using a digital inverted microscope with 4X magnification (AMG EVOS fl; Advanced Microscopy Group, Bothell, WA, USA). The number of closed tubes, total tube length, branching point number, and the mean length of branches between two branching points were evaluated using ImageJ software in a ROI measuring 4,300 × 3,225 µm.

**MTT assay of cell viability**

Similarly, 3 × 10⁴ hCMEC/D3 cells seeded in sextuplicates in 96-well plates were incubated for 24 h. After washing twice in 0.1 M PBS, cells were cultured under regular conditions (21% O₂) or oxygen–glucose deprivation (OGD) that was induced by transferring the cells in glucose-free DMEM medium (Gibco/Life Technologies) and incubated at 1% O₂ in a hypoxia chamber (Toepffer Lab Systems, Göppingen, Germany). (a) sEVplatelet, (b) sEVnormoxic or (c) sEVhypoxic (as above) at various concentrations (0–250 µg/mL) were added. After 24 h, hCMEC/D3 cells exposed to OGD were washed and cell medium was replaced with regular
medium, to which sEVs were added as before. Viable cells were labeled with 10% MTT. Cells were fixed with DMSO (Sigma-Aldrich). Light absorbance was measured using a microplate absorbance reader (iMark™; Bio-Rad Laboratories, Hercules, CA, USA) at 570 nm wavelength.

Intraluminal MCAO and MSC-sEV delivery

Animal experiments were performed with local government approval (Northrhine-Westphalian State Agency for Nature, Environment and Consumer Protection, Recklinghausen; permission G1680/18) in accordance to E.U. guidelines (Directive 2010/63/EU) for the care and use of laboratory animals and reported based on Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. Experiments were strictly randomized. The experimenter performing the animal experiments and histochemical studies (C.W.) was fully blinded at all stages of the study by another researcher (N.H.) preparing the vehicle and sEV solutions. These solutions received dummy names (solution A, B, C, and D, or A, B, C, D, and E), which were unblinded after termination of the study. Animals were kept in a regular inverse 12 h:12 h light/dark cycle in groups of 5 animals/cage.

Focal cerebral ischemia was induced in male C57BL6/j mice (8–10 weeks; 22–25 g; Harlan Laboratories, Darmstadt, Germany) anesthetized with 1.0–1.5% isoflurane (30% O2, remainder N2O) by 40 min left-sided intraluminal MCAO [30]. Rectal temperature was maintained between 36.5 and 37.0 °C using a feedback-controlled heating system (Fluovac; Harvard apparatus, Holliston, MA, USA). Cerebral blood flow was recorded by laser Doppler flow (LDF) measurement using a flexible probe attached to the skull overlying the middle cerebral artery territory core. The left common and external carotid arteries were isolated and ligated, and the internal carotid artery was temporarily clipped. A silicon-coated nylon monofilament (Doccol Corp., Sharon, MA, USA) was introduced through a small incision into the common carotid artery and advanced to the carotid bifurcation for MCAO. Reperfusion was initiated by monofilament removal. Following termination of the surgeries, wounds were carefully sutured. For analgesia, buprenorphine (0.1 mg/kg; Reckitt Benckiser, Slough, UK) was s.c. administered 30 min before MCAO. For anti-inflammation, animals received daily i.p. carprofen (4 mg/kg; Bayer Vital, Leverkusen, Germany) injections post-MCAO.

Twenty-four, 72 and 120 h post-MCAO, 200 µl of (a) vehicle (normal saline), (b) sEVplatelet, (c) sEVnormoxic or (d) sEVhypoxic (equivalent released by 2 × 10⁶ cells, in normal saline) were administrated through the animals’ tail vein, as reported previously [7, 30]. In animals sacrificed 14 days post-MCAO, 100 µg control isotype IgG (clone 2A3; BioXCell, West Lebanon, NH, USA) or 100 µg anti-Ly6G antibody (clone 1A8; BioXCell) were intraperitoneally administered at 24 h, 72 h, 120 h, and 168 h post-MCAO for PMN depletion, in parallel with the delivery of 100 µg anti-rat kappa immunoglobulin light chain (clone MAR 18.5; BioXCell) at 48, 96, and 144 h, which was administered for the augmentation of PMN sequestering. Neurological deficits were evaluated at 1, 7, 14, 21, 28, 35 and 42 days post-MCAO by Clark scores.

Mice were excluded from the study when they met one of the following exclusion criteria: (1) prolonged surgery duration > 20 min, (2) drop of Laser Doppler flow < 75% after monofilament insertion, (3) lack of reperfusion after monofilament withdrawal or (4) > 20% weight loss, respiratory abnormalities (central apneas) or death. In mice sacrificed at 14 days post-MCAO, a total of 6 mice (1 isotype IgG/vehicle, 2 isotype IgG/sEV normoxic, 1 isotype IgG/sEVhypoxic, 1 anti-Ly6G/vehicle, 1 anti-Ly6G/sEVhypoxic), and in mice sacrificed at 56 days post-MCAO, at total of 5 mice (1 vehicle, 2 sEVplatelet, 1 sEVnormoxic, 1 sEVhypoxic) were excluded. Animals excluded were substituted by new animals. For animals sacrificed at 56 days, 10 mice receiving vehicle, 6 mice receiving sEVplatelet, 9 mice receiving sEVnormoxic, and 9 mice receiving sEVhypoxic, and for animals sacrificed at 14 days, 6 mice receiving isotype IgG/vehicle, 5 mice receiving isotype IgG/sEVnormoxic, 8 mice receiving isotype IgG/sEVhypoxic, 7 mice receiving anti-Ly6G/vehicle, and 7 mice receiving anti-Ly6G/sEVhypoxic were prepared.

Fourteen or 56 days post-MCAO, mice were deeply anesthetized and sacrificed by transcardiac perfusion with 0.1 M phosphate-buffered saline (PBS) and 4% paraformaldehyde in 0.1 M PBS. For imaging of the reperfusion status of the brain tissue at the onset of MSC-sEV treatment, an additional control group of 5 mice exposed to intraluminal MCAO that were sacrificed after 24 h was prepared. These mice did not obtain any sEV or antibody treatment.

FITC-albumin hydrogel perfusion and whole-brain clearing for 3D light sheet fluorescence microscopy (LSFM)

In animals sacrificed at 14 days post-MCAO, 10 ml of a hand-warm (30 °C) 2% gelatin hydrogel containing 0.1% FITC-conjugated albumin, which had been filtered using Whatman filter paper (GE Healthcare Life Science, Little Chalfont, U.K.) and was protected from light, was transcerebrally infused into the animals’ aorta immediately following PFA infusion. Brains were subsequently removed, post-fixed overnight at 4 °C in 4% PFA in 0.1 M PBS and dehydrated through a 30%, 60%, 80%, and 100% tetrahydrofuran (THF; Sigma-Aldrich) gradient [22]. Brain clearing was achieved with ethyl cinnamate (ECI; Sigma-Aldrich).
3D LSFM and microvasculature analysis

The FITC-albumin labeled vasculature of cleared brains was scanned by a light sheet microscope (Ultramicroscope Blaze, LaVision BioTec, Gottingen, Germany) that was equipped with a 488 nm laser. Horizontal overview images of the cleared brain were taken using a 1.6 × objective. Serial images of the striatum and cortex were acquired at 2 μm steps using a 6.4 × objective. In each animal, two regions of interest (ROI) measuring 500 μm × 500 μm × 1000 μm (in the X, Y and Z planes, respectively) in the dorsolateral striatum were analyzed using Imaris (Bitplane, Zurich, Switzerland) software with 3D rendering software package, as described previously [22]. Following image segmentation, skeletonization and 3D reconstruction, a comprehensive set of microvascular network characteristics, that is, microvascular length density, branching point density, mean branch length between two branching points, and microvascular tortuosity, were determined.

Brain volumetry

Twenty-μm-thick coronal brain cryostat sections of mice sacrificed at 56 days post-MCAO collected at 1 mm intervals across the forebrain were stained with cresyl violet. Using Imaged software, the striatum volume and brain volume ipsilateral and contralateral to the stroke were determined, of which ipsilateral-to-contralateral volume ratios were formed.

Immunohistochemical analysis of microvascular density, neuronal survival, and astrocytic scar formation

Twenty-μm-thick sections obtained from the rostrocaudal level of the bregma of the same mice were rinsed three times for 5 min in 0.1 M PBS and immersed in 0.1 M PBS containing 0.1% triton (PBS-T) containing 10% normal donkey serum for 10 min. Sections were incubated overnight at 4 °C in monoclonal rat anti-CD31 (#550,274; clone MEC13.3; BD Biosciences, Heidelberg, Germany), monoclonal rabbit anti-neuronal nuclear antigen (NeuN; #ab177487; clone EPR12763; Abcam), or monoclonal rat anti-CD31 (#550,274; clone MEC13.3; BD Biosciences, Heidelberg, Germany) that was stained with cresyl violet. Using Imaged software, the striatum volume and brain volume ipsilateral and contralateral to the stroke were determined, of which ipsilateral-to-contralateral volume ratios were formed.

hCMEC/D3 cells seeded in 6-well plates were exposed to (a) control conditions, (b) sEVplatelet, (c) sEVnormoxic or (d) sEVhypoxic (50 μg/mL each) for 24 h, followed by RNA extraction using the miRNeasy FFPE kit (Qiagen, Hilden, Germany). RNA concentration was measured using a Qubit fluorometer (Life Technologies). RNA integrity was assessed using a Fragment Analyzer (Advanced Analytical Inc., Ames, IA, USA) using the DNF-489 standard sensitivity RNA analysis kit.

The commercially available nCounter miRNA Expression Assay v2.1 (NanoString Technologies, Seattle, WA, USA) containing probes and miRTags for 800 important miRNAs described in the context of cell proliferation and cancer was chosen for miRNA expression analysis. Five potential reference genes (ACTB, B2M, GAPDH, RPL19, RPLP0) were included in the CodeSet for biological normalization purposes. Probe sets and miRTags for each target in the CodeSet were designed and synthesized at NanoString Technologies. Samples containing 100 ng total RNA were analyzed for each sample (in a final volume of 3 μl). The sample preparation in the nCounter Prep Station (NanoString Technologies) was carried out using the high-sensitivity protocol (3 h preparation). The cartridges were measured in 555 fields of view in the nCounter Digital Analyzer (NanoString Technologies).

Data processing was performed using the R statistical programming environment (v3.2.3) using the NanoString-Norm and the NAPPA package (NanoString Technologies), respectively. Considering the counts obtained for positive control probe sets, raw NanoString counts for each gene were subjected to a technical factorial normalization, carried out by subtracting the mean counts plus two standard deviations from the CodeSet inherent negative controls. Afterwards, a biological normalization using the top 100 expressed miRNAs was performed. In brief, gene expression stability measures (M) were calculated using the geNorm algorithm. All sample counts were normalized against the geometric mean of the normalization counts. To overcome basal noise, counts with p > 0.05 versus negative controls in one-sided Wilks t tests plus two standard deviations were interpreted as not expressed. Normal distribution of data was
evaluated using Shapiro–Wilk tests. Based on the results, either parametric or non-parametric were applied, as appropriate, and p values were adjusted for the false discovery rate.

**Liquid chromatography/tandem mass spectrometry (LC/MS–MS)**

Proteins of (a) sEVplatelet, (b) sEVnormoxic or (c) sEVhypoxic (50 µg/mL each) were isolated using CO2-micro-80 S-Trap filters (Protifi, Huntington, NY, USA). To this end, 25 µg protein of each sEV lysate was solubilized in 5% sodium dodecyl sulfate (SDS) triethylammonium bicarbonate (pH 7.55). Disulfide bonds were broken using 20 mM DTT at 60 °C for 30 min. After cooling to room temperature, the sample was alkylated in the dark with 20 mM iodoacetamide for 30 min. Afterwards, phosphoric acid was added to a final concentration of 1.2%. Following resuspension, six volume equivalents of S-TRAP binding buffer (90% methanol; 100 mM triethylammonium bicarbonate, pH 7.19) were added. The sample was loaded on an S-Trap filter, centrifuged for 30 s at 4,000 rpm, and the flow-through discarded. The filter bound protein was washed 3 times according to the previous step; the filter was transferred into a fresh tube and incubated with the digest solution (50 mM ammonium bicarbonate, pH 7.8, 0.2 M guanidine hydrochloride and trypsin; Sigma-Aldrich) in a 20:1 ratio at 47 °C for 2 h. The elution of peptides was ensured by three elution steps for 1 min and 4,000 rpm (step 1: 50 mM ammonium bicarbonate, step 2: 0.2% formic acid in H2O, and step 3: 0.2% formic acid and 50% acetonitrile [ACN]). The obtained solution was frozen at −80 °C, and the buffer exchanged against 1% trifluoroacetic acid (TFA). Post-digestion quality control was performed on a monolithic high-performance liquid chromatography–tandem mass spectrometry (HPLC–MS/MS) as described previously [4].

To achieve a higher identification rate, samples were dried under vacuum, resuspended in 10 mM ammonium acetate (pH 8.0; buffer A), and fractionated on an Ultimate 3000 LC (Thermo Fisher Scientific). Peptides were separated on a 1 mm × 150 mm C18 (ZORBAX 300SB-C18, pore size 300 Å, 5 µm particle size; Agilent Technologies, Santa Clara, CA, USA) column with a 45 min LC gradient ranging from 3 to 45% buffer B (84% ACN in 10 mM ammonium acetate, pH 8.0) at a flow rate of 12.5 μL/min resulting in 10 fractions of each sample. Each fraction was dried and resuspended in 15 μL of 0.1% TFA for nano-liquid chromatography–tandem mass spectrometry (LC–MS/MS) analysis, which was performed using an Ultimate 3000 nano-LC system coupled to an LTQ Orbitrap Velos instrument (Thermo Fisher Scientific) using pre-column trap columns (100 µm × 2 cm, C18 Acclaim Pepmap viper) and main columns (75 µm × 50 cm, C18 Acclaim Pepmap viper; Thermo Fisher Scientific). A 118 min LC gradient ranging from 3 to 42% of buffer B (84% ACN, 0.1% TFA) at a flow rate of 250 nL/min was used. The ten most intense ions were fragmented and the data qualitatively analyzed. Unfractionated samples were prepared and analyzed the same way on an Orbitrap Fusion Lumos (Thermo Fisher Scientific). MS survey scans were acquired from 300 to 1500 m/z at a resolution of 60,000, using an AGC target value of 4 × 10^5 and a maximum injection time of 70 ms. Here, a 185 min LC gradient ranging from 3 to 35% of buffer B (84% ACN, 0.1% TFA) at a flow rate of 250 nL/min was used, and the ten most intense ions were fragmented and the data analyzed. Normal distribution of data was evaluated using Shapiro–Wilk tests.

**Statistical analysis**

For statistical analysis, a SPSS for Windows software package (version 22.0) was used. Data were evaluated by one-way or two-way analysis of variance (ANOVA) followed by least significant differences (LSD) tests (≥3 groups, normally distributed data) or two-sided t tests (2 groups, normally distributed data) or by Kruskal–Wallis tests (≥3 groups, non-normally distributed data) or Mann–Whitney U tests (2 groups, non-normally distributed data), as adequate. Results are shown as mean ± standard deviation (SD) values (angiogenesis assays) or as median values ± interquartile ranges (IQR) with minimum and maximum data as whiskers (in vivo data; miRNA expression analyses). P values <0.05 were considered significant. Data supporting our findings are available from the corresponding author on reasonable request.

**Results**

sEV preparations obtained from hypoxic MSCs dose-dependently increase cerebral microvascular endothelial cell proliferation

During angiogenesis, endothelial cells proliferate, migrate, and form capillary tubes [14]. To account for these processes, we evaluated these features using the hCMEC/D3 cell line. While sEVs obtained from MSC cell culture media (sEVplatelet, Fig. 1A, D) or sEVs from ‘normoxic’ MSCs (sEVnormoxic, source 41.5; Fig. 1B, D) did not influence endothelial proliferation at any dose examined, sEVs obtained from hypoxic MSCs (sEVhypoxic, again source 41.5) dose-dependently increased the proliferation of hCMEC/D3 cells (Fig. 1C, D). This increase was statistically significant between doses of 1 and 100 µg/mL and reached maximum levels at 50 µg/mL. Higher doses (250 µg/mL) did not promote endothelial proliferation. A separate analysis of three independent preparations of 41.5 MSC-sEVs revealed that sEVhypoxic consistently increased hCMEC/
D3 cell proliferation, whereas sEV<sub>platelet</sub> or sEV<sub>normoxic</sub> did not (Suppl. Fig. 4A–C). In view of these findings, we performed additional studies using sEVs obtained from MSCs of another donor (source 16.3). Again sEV<sub>hypoxic</sub>, but not sEV<sub>platelet</sub> or sEV<sub>normoxic</sub> increased hCMEC/D3 cell proliferation (Suppl. Fig. 5).

**sEV preparations obtained from hypoxic MSCs dose-dependently increase cerebral microvascular endothelial cell migration and tube formation**

Likewise, sEV<sub>hypoxic</sub>, but not sEV<sub>platelet</sub> or sEV<sub>normoxic</sub> obtained from 41.5 MSCs dose-dependently increased hCMEC/D3 cell transwell migration (Fig. 2A–C) and tube formation (Fig. 3A–C). Increases in transwell migration and tube formation were statistically significant at doses of 1–250 µg/mL and 0.1–100 µg/mL, respectively. Maximum effects were noted at doses of 50 µg/mL. In-depth analysis of tube formation using the 50 µg/mL dose revealed that sEV<sub>hypoxic</sub> consistently increased hCMEC/D3 cell migration and tube formation, whereas sEV<sub>platelet</sub> or sEV<sub>normoxic</sub> did not (Suppl. Figs. 6A–C, 7A–C). In view of these findings, we also performed studies using sEVs obtained from MSCs of six other donors (sources 16.3, 117.3, 126.7, 142.1, 152.6, and 153.3). Again, sEV<sub>hypoxic</sub> but not sEV<sub>platelet</sub> or sEV<sub>normoxic</sub> consistently increased hCMEC/D3 cell migration and tube formation (Suppl. Fig. 8A–E).

**sEV preparations obtained from hypoxic MSCs promote the post-ischemic survival of cerebral microvascular endothelial cells**

In ischemic tissues, the balance of endothelial proliferation and degeneration crucially determines vascular remodeling [14]. Hence, we evaluated the effects of MSC-sEVs on the viability of hCMEC/D3 cells cultured under regular ‘normoxic’ conditions and hCMEC/D3 cells exposed to 24 h OGD followed by 6 h reoxygenation/recultivation by MTT assays. The viability of hCMEC/D3 cells cultured under regular ‘normoxic’ conditions (21% O<sub>2</sub>; sEV<sub>normoxic</sub>) was not influenced by sEVs at any of the doses examined (Figs. 4A–C; Suppl. Fig. 8F), indicating lack of sEV toxicity. On the other hand, sEV<sub>hypoxic</sub> but not sEV<sub>platelet</sub> or sEV<sub>normoxic</sub> dose-dependently increased the survival of hCMEC/D3 cells exposed to 24 h OGD followed by 6 h reoxygenation/recultivation (Fig. 4D–F).
sEV preparations obtained from hypoxic MSCs regulate a distinct set of miRNAs in cerebral microvascular endothelial cells

To identify mechanisms via which sEVs promote cerebral angiogenesis, we exposed hCMEC/D3 cells to control conditions (no sEV exposure), sEV_{platelet}, sEV_{normoxic} or sEV_{hypoxic} at the dose that had strongest effects in the endothelial proliferation, migration, and tube formation assays (50 µg/mL) and examined the effects of sEVs on miRNA levels by NanoString gene expression analysis. Of 800 miRNAs examined, 6 miRNAs were differentially regulated by sEV_{hypoxic} compared with control conditions not receiving sEVs, sEV_{platelet} and sEV_{normoxic}. Three of these were upregulated (miR-126-3p, miR-140-5p, let-7c-5p, Fig. 5A–C) and three were downregulated (miR-186-5p, miR-370-3p, miR-409-3p; Fig. 5D–F) by sEV_{hypoxic}. KEGG pathway analysis by means of miRPathDB 2.0 (https://mpd.bioinf.uni-sb.de/mirnas.html; accessed April 20th, 2021) revealed that these miRNAs were associated with neurotrophin signaling (miR-126-3p, let-7c-5p), focal adhesion (miR-126-3p, miR-186-5p), VEGF signaling (miR-126-3p), leukocyte transendothelial migration (miR-126-3p), adherens junction (miR-409-3p) and cancer (miR-126-3p, miR-140-5p, let-7c-5p) pathways.

sEV preparations obtained from hypoxic MSCs are enriched for growth factor pathway-associated proteins and extracellular matrix proteins/proteases and reduced for proteins involved in oxidative metabolism

To identify proteins in sEVs obtained from hypoxic MSCs that confer angiogenic properties, we compared the proteome of sEV_{hypoxic} and sEV_{normoxic} by LC/MS–MS. 52 proteins were differentially abundant in sEV_{hypoxic} and sEV_{normoxic} preparations. 19 were significantly enriched and 33 significantly reduced in sEV_{hypoxic}. These proteins are summarized in Tables 1 and 2. Pathway analysis via KEGG Mapper (https://www.genome.jp/kegg/tool/map_pathway1.html; accessed April 21st, 2021) showed that proteins enriched in sEV_{hypoxic} compared with sEV_{normoxic} preparations were involved in (a) extracellular matrix (ECM)–receptor interaction (collagen alpha-1(VI) chain [COL6A1], collagen alpha-2(VI) chain [COL6A2], collagen alpha-3(VI) chain [COL6A3], tenascin-C [TNC]), (b) focal adhesion (COL6A1, COL6A2, COL6A3, TNC), (c) leukocyte transendothelial migration (72 kDa type IV collagenase [MMP2]), (d) protein digestion and absorption (collagen alpha-1(V) chain [COL5A1], COL6A1, COL6A2, COL6A3, collagen alpha-1(XII) chain [COL12A1]) and
(e) cholesterol metabolism (apolipoprotein A-II [APOA2], apolipoprotein A-IV [APOA4], angiopoietin-related protein-4 [ANGPTL4]). A number of growth factor-associated proteins (IGF binding protein-3 [IGFBP3], transforming growth factor [TGF]-β-induced protein ig-h3 [TGFBI], latent-TGF-β-binding protein-2 [LTBP2], EGF-like repeat and discoidin I-like domain-containing protein-3 [EDIL3]) were also found. On the contrary, proteins reduced in sEVhypoxic compared with sEVnormoxic preparations were associated with (a) metabolic pathways (phosphatidylinositol-glycan-specific phospholipase D [GPLD1], 6-phosphogluconate dehydrogenase [PGD], peroxiredoxin-6 [PRDX6]), ECM–receptor interaction (fibronectin [FN1], von Willebrand factor [VWF]), (b) endocytosis (F-actin-capping protein subunit alpha-1 [CAPZA1]), (c) focal adhesion (FN1, VWF), (d) regulation of the actin cytoskeleton (FN1, kininogen-1 [KNG1]), (e) the complement system (mannan-binding lectin serine protease-2 [MASP2], heparin cofactor-2 [SERPIND1], KNG1, complement C1q subcomponent subunit-C [C1QC], complement C1s subcomponent [C1S], VWF) and platelet activation (tyrosine protein kinase Lyn [LYN], VWF).

**sEV preparations obtained from hypoxic MSCs increase microvascular density and long-term neuronal survival, and promote neurological recovery after focal cerebral ischemia in mice**

To evaluate, if the angiogenic effect of sEVs obtained from hypoxic MSCs translates into enhanced post-stroke angiogenesis and brain remodeling in vivo, mice were exposed to transient intraluminal MCAO followed by delivery of vehicle, sEVplatelet, sEVnormoxic (equivalent released by 2 × 10⁶ cells, in normal saline; MSC source 41.5, preparation A) or sEVhypoxic (equivalent released by 2 × 10⁶ cells, in normal saline; MSC source 41.5, preparation A) at 24, 72 and 120 h post-ischemia. Neurological recovery was evaluated by Clark scores. After animal sacrifice at 56 days post-ischemia, microvascular length, neuronal survival and glial scar formation were immunohistochemically evaluated on...
coronal 20 µm sections in the ischemic striatum and cortex at the rostrocaudal level of the bregma, which represents the core of the vascular territory of the middle cerebral artery. Importantly, sEVhypoxic, but not sEVnormoxic or sEVplatelet increased microvascular length in the previously ischemic striatum (Fig. 6A), which is most vulnerable to brain injury in the intraluminal MCAO model, and the peri-infarct parietal cortex (Suppl. Fig. 9A), but not the infarct-remote motor cortex (Suppl. Fig. 9B). Moreover, sEVhypoxic, but not sEVnormoxic or sEVplatelet increased neuronal survival in the ischemic striatum (Fig. 6B), but did not influence astrocytic scar formation around the brain infarct (Fig. 6C), which were evaluated as surrogates of brain parenchymal remodeling. Of note, brain tissue protection by sEVhypoxic was associated with an increased volume of the ischemic striatum (Fig. 6D) and ischemic brain hemisphere (Fig. 6E) at 56 days post-MCAO and enhanced neurological recovery (Fig. 6F). LDF recordings during and after MCAO did not differ between groups (Suppl. Fig. 9C). Our data demonstrate a robust neurovascular restorative signature induced by hypoxia-conditioned MSC-sEV preparations.

In view of the elevation of microvascular density by sEVhypoxic, but not sEVnormoxic, we subsequently performed an in depth analysis of microvascular network characteristics in 3D by LSFM in mice exposed to transient intraluminal MCAO treated with vehicle, sEVnormoxic (MSC source 41.5; as above) or sEVhypoxic (MSC source 41.5; as above) at 24, 72 and 120 h post-MCAO. Since PMNs have previously been shown by us to mediate acute neuroprotective effects of MSC-sEVs [30], we concomitantly depleted PMNs in two subgroups by anti-Ly6G antibody delivery. Animals were sacrificed at 14 days post-MCAO. For imaging of the reperfusion status at the onset of MSC-sEV treatment, mice exposed to intraluminal MCAO which did not receive any treatment and which were sacrificed at 24 h post-MCAO were also examined. In these mice, a pronounced reduction of microvascular length density by 58.1% and 42.0%, respectively, was noted in the previously ischemic cortex and striatum alongside an even larger reduction of branching point density by 74.9% and 51.8%, respectively, in the previously ischemic cortex and striatum (Suppl. Table 2). Microvascular mean branch length and tortuosity were unchanged (Suppl. Table 2). Notably, sEVhypoxic, but not sEVnormoxic increased microvascular length and branching point density and reduced mean branch length and tortuosity in the previously ischemic

---

**Fig. 4** sEVs from hypoxic MSCs increase the survival of cerebral microvascular endothelial cells exposed to oxygen–glucose deprivation (OGD), but do not influence the viability of cells cultured under regular ‘normoxic’ conditions. Relative absorbance of hCMEC/D3 cells cultured under (A–C) regular ‘normoxic’ conditions (21% O2) or (D–F) 24 h OGD (1% O2, glucose deprivation) followed by 6 h reoxygenation (21% O2)/glucose recultivation, determined in a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay after exposure to different concentrations of A, D sEVs obtained from MSC culture media that contain platelet lysates (sEVplatelet), B, E sEVs obtained from MSCs (source 41.5) cultured under regular ‘normoxic’ conditions (21% O2; sEVnormoxic) or C, F sEVs obtained from MSCs (source 41.5) cultured under hypoxic conditions (1% O2; sEVhypoxic). Data are mean±SD values (n=3 independent experiments [in A–E], 8 independent experiments [in F]). **p<0.01, ***p<0.001 compared with control.
brain tissue at 14 days post-MCAO (Fig. 7A–J). LDF recordings during and after MCAO did not differ between groups (Suppl. Fig. 10). Interestingly, PMN depletion by anti-Ly6G antibody abolished the effects of sEVhypoxic on microvascular network characteristics (Fig. 7A–J).

**Discussion**

We herein show that sEVs obtained from supernatants of MSCs cultured under hypoxic conditions (1% O2; sEVhypoxic) or sEVs from supernatants of MSCs cultured under regular ‘normoxic’ conditions (21% O2; sEVnormoxic) or sEVs obtained from MSCs (source 41.5) cultured under regular ‘normoxic’ conditions (1% O2; 50 µg/mL; sEVhypoxic). Data are box plots with medians (lines inside boxes/means (crosses inside boxes) ± interquartile ranges (IQR; boxes) with minimum/maximum values as whiskers (n=4–6 samples per group). *p<0.05, **p<0.01, ***p<0.001 compared with control/††p<0.01, †††p<0.001 compared with sEVplatelet/‡p<0.05, ‡‡p<0.01 compared with sEVnormoxic.
as shown by NanoString gene expression analysis, which were upregulated (miR-126-3p, miR-140-5p, let-7c-5p) or downregulated (miR-186-5p, miR-370-3p, miR-409-3p) by sEVhypoxic. Proteome analysis revealed 52 proteins that were differentially abundant in sEVhypoxic and sEVnormoxic, 19 of which were enriched and 33 reduced in sEVhypoxic. In an in vivo model of ischemic stroke in mice, that is, intraluminal MCAO, sEVhypoxic, but not sEVplatelet or sEVnormoxic increased microvascular length and branching point density in the previously ischemic striatum and cortex over up to 56 days, increased long-term neuronal survival, reduced brain atrophy and enhanced neurological recovery. Hence, sEVhypoxic induced a robust brain remodeling response. In vivo, the proangiogenic effect of MSC-sEVs depended on the presence of PMNs. In PMN-depleted mice, sEVhypoxic did not promote microvascular network remodeling.

Accordingly to this study, the restorative effects of MSC-derived sEV preparations on the proliferation, migration and tube formation of cerebral microvascular endothelial cells in vitro and post-ischemic angiogenesis and brain remodeling in the post-acute stroke phase in vivo differ from their effects in the acute stroke phase, in which our group has previously shown in the same mouse intraluminal MCAO model that sEVhypoxic and sEVnormoxic very similarly reduced infarct volume and neuronal injury [30]. In this earlier study, sEVhypoxic, but not sEVnormoxic, reduced blood–brain barrier permeability evaluated by IgG extravasation [30], suggesting that microvascular actions of sEVs are modified by hypoxic preconditioning. The prevention of PMN brain entry played a crucial role in the acute neuroprotective effects of MSC-sEVs [30]. In mice exhibiting PMN depletion by anti-Ly6G antibody delivery, MSC-sEVs did not have any additional effect on infarct volume, neuronal survival or the brain infiltration of monocytes and lymphocytes [30]. PMNs exacerbate ischemic injury in the acute stroke phase [15, 24]. While this detrimental role of PMNs is meanwhile well established [13], the proangiogenic role of PMNs in the post-acute stroke phase is new. Our data suggest a dual role of PMNs in the ischemic brain. The mechanisms underlying PMN-associated angiogenesis will deserve further studies. Besides the release of proteases and reactive oxygen species by PMNs that facilitate ECM remodeling, alterations in the PMN differentiation in response to sEVs might play a role.

The effects of MSC-sEVs on microvessels apparently depend on tissues and pathophysiological states. In cancer tissues, for example, MSC-sEVs may promote or inhibit angiogenesis depending on the precise MSC source and tumor microenvironment [6, 18, 41]. In cell culture, sEVs obtained from normoxic MSCs increased the tube formation of HUVECs in one [26], but not another [1] study. In the study exhibiting induction of tube formation by sEVnormoxic [26], signaling pathways important in wound healing (Akt,

### Table 1 Proteins significantly enriched in sEV preparations obtained from MSCs cultured under hypoxic conditions

| Protein (Gene name) | Gene ID | Ratio |
|---------------------|---------|-------|
| 72 kDa type IV collagenase (MMP2) | 4313 | 2.609 |
| Collagen alpha-2(VI) chain (COL6A2) | 1292 | 2.506 |
| Collagen alpha-3(VI) chain (COL6A3) | 1293 | 2.472 |
| Collagen alpha-1(VI) chain (COL6A1) | 1291 | 2.447 |
| Insulin-like growth factor-binding protein-3 (IGFBP3) | 3486 | 2.322 |
| Angiopoietin-related protein-4 (ANGPTL4) | 51,129 | 2.213 |
| Apolipoprotein A-IV (APOA4) | 337 | 2.177 |
| Collagen alpha-1(XII) chain (COL12A1) | 1303 | 2.059 |
| Transforming growth factor-beta-induced protein ig-h3 (TGFB1) | 7045 | 1.962 |
| Collagen alpha-1(V) chain (COL5A1) | 1289 | 1.930 |
| Latent transforming growth factor beta-binding protein-2 (LTBP2) | 4053 | 1.895 |
| Apolipoprotein A-II (APOA2) | 336 | 1.883 |
| Cell migration-inducing and hyaluronan-binding protein (CEMIP) | 57,214 | 1.873 |
| Serum amyloid A-4 protein (SAA4) | 6291 | 1.806 |
| Tenascin-C (TNC) | 3371 | 1.682 |
| HtrA serine protease (HTRA1) | 5654 | 1.650 |
| Lactadherin (MFGE8) | 4240 | 1.613 |
| Protein-lysine-6-oxidase (PL6O) | 348,959 | 1.593 |
| Epidermal growth factor-like repeat and discoidin I-like domain-containing protein-3 (EDIL3) | 10,085 | 1.515 |

The column in the center presents gene IDs. The right column exhibits ratios of protein abundances in sEVs obtained from 41.5 MSCs cultured under hypoxic conditions (1% O2; sEVhypoxic) and sEVs obtained from MSCs cultured under regular ‘normoxic’ conditions (21% O2; sEVnormoxic) determined by LC/MS–MS.
extracellular-regulated kinase-1/2, and signal transducer and activator of transcription-3) were activated and growth factors (hepatocyte growth factor, insulin-like growth factor-1, nerve growth factor, stromal-derived growth factor-1) were elevated by sEVs. A third study on MSC-sEVs in HUVECs described that the angiogenic effects of sEVs closely depended on the presence of HIF-1α in parental MSCs [9]. MSCs overexpressing HIF-1α were found to exhibit an increased abundance of the Notch ligand Jagged-1 in sEVs [9]. Jagged-1-containing sEVs increased angiogenesis in Matrigel-based tube formation and plug assays [9]. These effects were blocked by prior incubation of sEVs with an anti-Jagged-1 antibody. The observation that sEVhypoxic specifically induce angiogenesis in cerebral microvessels to the best of our knowledge is new. sEVs obtained from ‘normoxic’ adipose-derived MSCs have previously been shown to promote the migration and tube formation of primary rat brain microvascular endothelial cells exposed to OGD [38].

By means of NanoString expression analysis, we identified a set of miRNAs, which were upregulated (miR-126-3p, miR-140-5p, let-7c-5p) or downregulated (miR-186-5p, miR-370-3p, miR-409-3p) in hCMEC/D3 cells by sEVhypoxic. It has previously been noted that MSC-derived sEVhypoxic exhibit higher miR-126 levels than sEVnormoxic [20]. In HUVECs, the elevated miR-126 levels conferred

### Table 2

| Protein (Gene name) | Gene ID | Ratio |
|---------------------|---------|-------|
| Inter-alpha-trypsin inhibitor heavy chain H4 (ITIH4) | 3700 | 0.208 |
| Heparin cofactor-2 (SERPIND1) | 3053 | 0.280 |
| Alpha-2-HS glycoprotein (AHSG) | 197 | 0.301 |
| Kininogen-1 (KNG1) | 3827 | 0.409 |
| Lysyl oxidase homolog-4 (LOXL4) | 84,171 | 0.422 |
| Retinol-binding protein-4 (RBP4) | 5950 | 0.427 |
| Proteoglycan-4 (PRG4) | 10,216 | 0.443 |
| Signal peptide, CUB and EGF-like domain-containing protein-3 (SCUBE3) | 222,663 | 0.456 |
| Cholesteryl ester transfer protein (CETP) | 1071 | 0.482 |
| Secreted phosphoprotein-2 (SPP2) | 6694 | 0.495 |
| von Willebrand factor (VWF) | 7450 | 0.498 |
| Immunoglobulin heavy variable 4–28 (IGHV4-28) | 28,400 | 0.552 |
| Inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) | 3699 | 0.576 |
| Coiled-coil domain-containing protein-73 (CCDC73) | 493,860 | 0.595 |
| Mannan-binding lectin serine protease-2 (MASP2) | 10,747 | 0.598 |
| Lymphocyte antigen-6 complex locus protein G6f (LY6G6f) | 259,215 | 0.605 |
| Fibulin-1 (FBLN1) | 2192 | 0.606 |
| Peroxiredoxin-6 (PRDX6) | 9588 | 0.607 |
| Phosphatidylinositol-glycan-specific phospholipase D (GPLD1) | 2822 | 0.610 |
| Complement C1s subcomponent (C1S) | 716 | 0.614 |
| F-actin-capping protein subunit alpha-1 (CAPZA1) | 829 | 0.617 |
| Tyrosine protein kinase Lyn (LYN) | 4067 | 0.618 |
| Galectin-1 (LGALS1) | 3956 | 0.643 |
| Complement C1q tumor necrosis factor-related protein-3 (C1QTNF3) | 114,899 | 0.649 |
| Complement C1q subcomponent subunit-C (C1QC) | 714 | 0.651 |
| Kallistatin (SERPIN4) | 5267 | 0.657 |
| Haptoglobin (HP) | 3240 | 0.657 |
| Fibronectin (FN1) | 2335 | 0.659 |
| Procollagen C-endopeptidase enhancer-2 (PCOLCE2) | 26,577 | 0.662 |
| IgGf-binding protein (FCGBP) | 8857 | 0.662 |
| Endoplasmin (HSP90B1) | 7184 | 0.664 |
| Carboxypeptidase N subunit-2 (CPN2) | 1370 | 0.667 |
| 6-phosphogluconate dehydrogenase, decarboxylating (PGD) | 5226 | 0.667 |

The column in the center presents gene IDs. The right column exhibits ratios of protein abundances in sEVs obtained from MSCs cultured under hypoxic conditions (1% O2; sEVhypoxic) and sEVs obtained from 41.5 MSCs cultured under regular ‘normoxic’ conditions (21% O2; sEVnormoxic) determined by LC/MS–MS.
angiogenic effects of sEVhypoxic [20]. miR-126 formation was HIF-1α-dependent. Indeed, HIF-1α knockdown decreased miR-126 levels in MSCs and MSC-sEVs, thereby abolishing their angiogenic properties [20]. In rats, sEVs from miR-126 overexpressing MSCs promoted angiogenesis and neurogenesis and reduced lesion volume after MCAO [16]. miR-126 overexpressing sEVs promoted the migration and tube formation of HUVECs [16]. miR-140-5p, on the other hand, was previously found to be increased in the ischemic brain of rats exposed to MCAO and hypoxic HUVECs [27]. In HUVECs, miR-140-5p transfection decreased endothelial proliferation, migration and tube formation probably by mechanisms involving VEGF-A transcription, as indicated by luciferase reporter assay studies [27]. Let-7 miRNAs are hypoxia-responsive miRNAs induced in a HIF1α and argonaute-1 (AGO1)-dependent way in HUVECs which promote angiogenesis, as shown in let-7a and let-7e overexpression and antagomir-mediated downregulation studies using Matrigel-based tube formation and plug assays [5]. miR-186 and miR-370 have anti-angiogenic effects in retinoblastoma [34] and human dermal microvascular endothelial cells, HUVEC spheroids and mouse aortic rings [11], respectively. miR-409-3p inhibits proliferation, vasogenic mimicry and lung metastasis of HT1080 fibrosarcoma cells [31]. A role of the latter miRNAs in the proliferation, migration and tube formation of cerebral microvascular endothelial cells has so far not been shown.
Proteome analysis by LC/MS–MS revealed 52 proteins that were differentially abundant in sEV preparations obtained from MSC-derived sEVhypoxic and sEVnormoxic, 19 of which were enriched and 33 reduced. Among those proteins enriched in sEVhypoxic were proteins involved in ECM–receptor interaction (COL6A1, COL6A2, COL6A3, TNC), focal adhesion (COL6A1, COL6A2, COL6A3, TNC), leukocyte transendothelial migration (MMP2), and various other biological processes.

**Fig. 7** sEVs obtained from hypoxic MSCs increase microvascular remodeling following ischemic stroke, which is abolished in the absence of polymorphonuclear neutrophils (PMNs) in vivo. Microvascular network characteristics, that is, A, E microvascular length density, B, F branch point density, C, G mean branch length, and D, H tortuosity in the previously ischemic A–D cerebral cortex and E–H striatum evaluated by 3D light sheet microscopy in mice exposed to 40 min MCAO followed by 14 days survival, in which vehicle (normal saline), sEVs released by MSCs (source 41.5) cultured under ‘normoxic’ conditions (21% O2; sEVnormoxic; equivalent released by 2 × 10⁶ cells) or sEVs released by MSCs (source 41.5) cultured under hypoxic conditions (1% O2; sEVhypoxic; equivalent released by 2 × 10⁶ cells) were intravenously administered at 1, 3, and 5 days post-MCAO, while control (isotype) IgG or anti-Ly6G (clone 1A8; Ly6G indicates lymphocyte antigen-6, locus G) antibody was intraperitoneally applied at 1, 3, 5, and 7 days post-MCAO. I Representative axial overview images of a vehicle-treated mouse brain with magnifications depicting the regions of interest in the ischemic striatum and cortex, in which microvascular network characteristics were determined. J Representative maximum intensity projection (MIP) images in the ischemic cortex for the five experimental groups. Data are box plots with medians (lines inside boxes)/means (crosses inside boxes) ± IQR (boxes) with minimum/maximum values as whiskers (n = 6 animals isotype/vehicle, 5 animals isotype/sEV_normoxic, 8 animals isotype/sEVhypoxic, 7 animals anti-Ly6G/vehicle, 7 animals anti-Ly6G/sEVhypoxic). *p < 0.05 compared with isotype/vehicle/ ‡p < 0.05 compared with isotype/sEV_normoxic/#p < 0.05 compared with isotype/sEVhypoxic. Scale bars: 500 µm (in I)/100 µm (in J)
protein digestion and absorption (COL5A1, COL6A1, COL6A2, COL6A3, COL12A1) and cholesterol metabolism (APOA2, APOA4, ANGPTL4). A number of growth factor-associated proteins (IGFBP3, TGFBI, LTBP2, EDIL3) were also found. Enrichment of proteins belonging to the platelet-derived growth factor [PDGF], EGF and FGF pathways has previously been observed in sEV_hypoxic compared with sEV_normoxic [2]. Their study protocol differed from the present study in that the hypoxia stimulus was combined with fetal bovine serum starvation, mimicking conditions of growth factor deprivation in peripheral artery disease [2]. In their study, enrichment of various proteins belonging to the nuclear factor (NF)-κB and cholesterol/lipid biosynthesis pathways were furthermore noted [2]. Among the proteins identified, 72 kDa type IV collagenase (i.e., gelatinase-A, matrix metalloproteinase [MMP]-2) was also found [2]. Accumulation of the serine protease HTRA1 in MSC-sEVs has to be best of our knowledge not been shown. Among those proteins reduced in sEV_hypoxic were proteins involved in metabolic pathways (GPLD1, PGD, PRDX6), ECM–receptor interaction (FN1, VWF), endocytosis (CAPZA1), focal adhesion (FN1, VWF), regulation of the actin cytoskeleton (FN1, KNG1), the complement system (MASP2, SERPIND1, KNG1, C1QC, C1S, VWF) and platelet activation (LYN, VWF). The presence of coagulation and complement factors in MSC-sEVs has already been shown [8, 23]. In rat models of spinal cord injury, MSC-sEVs reduced complement activation [40]. Regarding the detection of coagulation and complement factors as components on MSC-sEVs, possible by-products enriched in sEVs originating from the plasma carelessly need to be considered. Such by-products might contribute to the mode of action of sEVs [33] and perhaps confer proangiogenic activities [32]. Whatever the mode of action or the active components of MSC-EV preparations may be, this study provides robust evidence that hypoxia-preconditioning should increase the efficacy of MSC-sEV preparations in ischemic stroke recovery.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00395-021-00881-9.

Author contributions DMH and BG designed the study in interaction with JG and CW; JG, CW, OS, TH, YQ, TT, VB, AMY, NH, DY, RD, YM, FDM, and PEM performed the experiments and analyzed the data together with DMH and BG; AP-W, CK, TRD, MG, and HEM provided methodical input; JG, CW, DMH, and BG drafted the manuscript; all authors critically revised it.

Funding Open Access funding enabled and organized by Projekt DEAL. Supported by ERA-NET EuroTransBio (EV Trust; to D.M.H. and B.G.), the German Research Foundation (HE3173/11–1, HE3173/12–1 and HE3173/13–1 within FOR2879; to D.M.H.), the National Authority for Science, Research and Innovation (UEFISCDI; PN-III-P4-ID-PCE-2016–0340, PN-III-P2-2.1-PED-2016–1013, PN-III-P4-ID-PCE-2016–0215; to D.M.H. and A.P.-W.), LeitmarktAgentur.

Availability of data and materials Data supporting this study will be made available to qualified researchers upon reasonable request.

Declarations

Conflicts of interest B.G. and D.M.H. hold patents for the application of extracellular vesicles for the treatment of inflammatory conditions (EP2687219A1 pending; US9877989B2 issued). B.G. is a Scientific Board member of Evox Therapeutics and Innovex Therapeutics SL. Besides, the authors report no conflicts of interest.

Ethics approval Performed with government approval (Northrhine-Westphalian State Agency for Nature, Environment and Consumer Protection, Recklinghausen; permission G1680/18).

Consent for publication All authors read and consented the final version of this paper.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Almeria C, Weiss R, Roy M, Tripisciano C, Kasper C, Weber V, Egger D (2019) Hypoxia conditioned mesenchymal stem cell-derived extracellular vesicles induce increased vascular tube formation in vitro. Front Bioeng Biotechnol 7:292. https://doi.org/10.3389/fbioe.2019.00292
2. Anderson JD, Johansson HJ, Graham CS, Vesterlund M, Pham MT, Bramlett CS, Montgomery EN, Mellema MS, Bardin RL, Contreras Z, Hoon M, Bauer G, Fink KD, Fury B, Hendrix KJ, Chedin F, El-Andaloussi S, Hwang B, Mulligan MS, Lehtij Ö, Nolta JA (2016) Comprehensive proteomic analysis of mesenchymal stem cell exosomes reveals modulation of angiogenesis via nuclear factor-kappaB signaling. Stem Cells 34:601–613. https://doi.org/10.1002/stem.2298
3. Börger V, Staubach S, Dittrich R, Stambouli O, Giebel B (2020) Scaled isolation of mesenchymal stem/stromal cell-derived extracellular vesicles. Curr Protoc Stem Cell Biol 55:e128. https://doi.org/10.1002/cpsc.128
4. Burkhart JM, Schumbrutzki C, Wörtelkamp S, Sickmann A, Zahedi RP (2012) Systematic and quantitative comparison of digest efficiency and specificity reveals the impact of trypsin quality on MS-based proteomics. J Proteom 75:1454–1462. https://doi.org/10.1016/j.jprot.2011.11.016
5. Chen Z, Lai TC, Jan YH, Lin FM, Wang WC, Xiao H, Wang YT, Sun W, Cui X, Li YS, Fang T, Zhao H, Padmanabhan C, Sun R, Wang DL, Jin H, Chau GY, Huang HD, Hsiao M, Shyy

NRW (to B.G.), and the European Union (European Regional Development Fund 2014–2020; to B.G.).
7. Doeppner TR, Herz J, Gorgens A, Schlechter J, Ludwig AK, De Palma M, Biziato D, Petrova TV (2017) Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer 17:457–474. https://doi.org/10.1038/nrc.2017.51

6. De Palma M, Biziato D, Petrova TV (2017) Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer 17:457–474. https://doi.org/10.1038/nrc.2017.51

5. Doeppner TR, Herz J, Gorgens A, Schlechter J, Ludwig AK, De Palma M, Biziato D, Petrova TV (2017) Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer 17:457–474. https://doi.org/10.1038/nrc.2017.51

4. Doeppner TR, Herz J, Gorgens A, Schlechter J, Ludwig AK, De Palma M, Biziato D, Petrova TV (2017) Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer 17:457–474. https://doi.org/10.1038/nrc.2017.51

3. Doeppner TR, Herz J, Gorgens A, Schlechter J, Ludwig AK, De Palma M, Biziato D, Petrova TV (2017) Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer 17:457–474. https://doi.org/10.1038/nrc.2017.51

2. Doeppner TR, Herz J, Gorgens A, Schlechter J, Ludwig AK, De Palma M, Biziato D, Petrova TV (2017) Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer 17:457–474. https://doi.org/10.1038/nrc.2017.51

1. Doeppner TR, Herz J, Gorgens A, Schlechter J, Ludwig AK, De Palma M, Biziato D, Petrova TV (2017) Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer 17:457–474. https://doi.org/10.1038/nrc.2017.51
29. Théry C, Witwer KW, Alcaraz MJ, Anderson JD, Tertel T, Görgens A, Giebel B (2020) Chapter four—analysis of individual extracellular vesicles by imaging flow cytometry. In: Spada S, Galluzzi (eds) Methods in enzymology, Volume 645 Extracellular vesicles Academic Press, Cambridge, pp 55–78.

28. Théry C, Witwer KW, Alcaraz MJ, Anderson JD, Tertel T, Görgens A, Giebel B (2020) Chapter four—analysis of individual extracellular vesicles by imaging flow cytometry. In: Spada S, Galluzzi (eds) Methods in enzymology, Volume 645 Extracellular vesicles Academic Press, Cambridge, pp 55–78.

27. Théry C, Witwer KW, Alcaraz MJ, Anderson JD, Tertel T, Görgens A, Giebel B (2020) Chapter four—analysis of individual extracellular vesicles by imaging flow cytometry. In: Spada S, Galluzzi (eds) Methods in enzymology, Volume 645 Extracellular vesicles Academic Press, Cambridge, pp 55–78.

26. Théry C, Witwer KW, Alcaraz MJ, Anderson JD, Tertel T, Görgens A, Giebel B (2020) Chapter four—analysis of individual extracellular vesicles by imaging flow cytometry. In: Spada S, Galluzzi (eds) Methods in enzymology, Volume 645 Extracellular vesicles Academic Press, Cambridge, pp 55–78.

25. Théry C, Witwer KW, Alcaraz MJ, Anderson JD, Tertel T, Görgens A, Giebel B (2020) Chapter four—analysis of individual extracellular vesicles by imaging flow cytometry. In: Spada S, Galluzzi (eds) Methods in enzymology, Volume 645 Extracellular vesicles Academic Press, Cambridge, pp 55–78.

24. Théry C, Witwer KW, Alcaraz MJ, Anderson JD, Tertel T, Görgens A, Giebel B (2020) Chapter four—analysis of individual extracellular vesicles by imaging flow cytometry. In: Spada S, Galluzzi (eds) Methods in enzymology, Volume 645 Extracellular vesicles Academic Press, Cambridge, pp 55–78.

23. Théry C, Witwer KW, Alcaraz MJ, Anderson JD, Tertel T, Görgens A, Giebel B (2020) Chapter four—analysis of individual extracellular vesicles by imaging flow cytometry. In: Spada S, Galluzzi (eds) Methods in enzymology, Volume 645 Extracellular vesicles Academic Press, Cambridge, pp 55–78.

22. Théry C, Witwer KW, Alcaraz MJ, Anderson JD, Tertel T, Görgens A, Giebel B (2020) Chapter four—analysis of individual extracellular vesicles by imaging flow cytometry. In: Spada S, Galluzzi (eds) Methods in enzymology, Volume 645 Extracellular vesicles Academic Press, Cambridge, pp 55–78.

21. Théry C, Witwer KW, Alcaraz MJ, Anderson JD, Tertel T, Görgens A, Giebel B (2020) Chapter four—analysis of individual extracellular vesicles by imaging flow cytometry. In: Spada S, Galluzzi (eds) Methods in enzymology, Volume 645 Extracellular vesicles Academic Press, Cambridge, pp 55–78.

20. Théry C, Witwer KW, Alcaraz MJ, Anderson JD, Tertel T, Görgens A, Giebel B (2020) Chapter four—analysis of individual extracellular vesicles by imaging flow cytometry. In: Spada S, Galluzzi (eds) Methods in enzymology, Volume 645 Extracellular vesicles Academic Press, Cambridge, pp 55–78.

19. Théry C, Witwer KW, Alcaraz MJ, Anderson JD, Tertel T, Görgens A, Giebel B (2020) Chapter four—analysis of individual extracellular vesicles by imaging flow cytometry. In: Spada S, Galluzzi (eds) Methods in enzymology, Volume 645 Extracellular vesicles Academic Press, Cambridge, pp 55–78.

18. Théry C, Witwer KW, Alcaraz MJ, Anderson JD, Tertel T, Görgens A, Giebel B (2020) Chapter four—analysis of individual extracellular vesicles by imaging flow cytometry. In: Spada S, Galluzzi (eds) Methods in enzymology, Volume 645 Extracellular vesicles Academic Press, Cambridge, pp 55–78.
Reventós J, Rigau M, Rohde E, Sammar M, Sánchez-Madrid F, Santaré́m N, Schallmoser K, Ostenfeld MS, Stoorvogel W, Stukelj R, Van der Grein SG, Vasconcelos MH, Wauben MH, De Wever O (2015) Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles 4:27066. https://doi.org/10.3402/jev.v4.27066

38. Yang Y, Cai Y, Zhang Y, Liu J, Xu Z (2018) Exosomes secreted by adipose-derived stem cells contribute to angiogenesis of brain microvascular endothelial cells following oxygen-glucose deprivation in vitro through microRNA-181b/TRPM7 axis. J Mol Neurosci 65:74–83. https://doi.org/10.1007/s12031-018-1071-9

39. Zhang ZG, Buller B, Chopp M (2019) Exosomes—beyond stem cells for restorative therapy in stroke and neurological injury. Nat Rev Neurol 15:193–203. https://doi.org/10.1038/s41582-018-0126-4

40. Zhao C, Zhou X, Qiu J, Xin D, Li T, Chu X, Yuan H, Wang H, Wang Z, Wang D (2019) Exosomes derived from bone marrow mesenchymal stem cells inhibit complement activation in rats with spinal cord injury. Drug Des Devel Ther 13:3693–3704. https://doi.org/10.2147/DDDT.S209636

41. Zhu W, Huang L, Li Y, Zhang X, Gu J, Yan Y, Xu X, Wang M, Qian H, Xu W (2012) Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett 315:28–37. https://doi.org/10.1016/j.canlet.2011.10.002

Authors and Affiliations

Jonas Gregorius1 · Chen Wang1 · Oumaima Stambouli2 · Tanja Hussner1 · Yachao Qi1 · Tobias Tertel2 · Verena Börger2 · Ayan Mohamud Yusuf1 · Nina Hagemann1 · Dongpei Yin1 · Robin Dittrich2 · Yanis Mouloud2 · Fabian D. Mairinger3 · Fouzi El Magraoui4 · Aurel Popa-Wagner5 · Christoph Kleinschnitz1 · Thorsten R. Doeppner6 · Matthias Gunzer4,7 · Helmut E. Meyer4,8 · Bernd Giebel2 · Dirk M. Hermann1

1 Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, Hufelandstraße 55, 45122 Essen, Germany
2 Institute of Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147 Essen, Germany
3 Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
4 Leibniz Institute for Analytical Sciences (ISAS), Dortmund, Germany
5 Center of Experimental and Clinical Medicine, University of Medicine and Pharmacy, Craiova, Romania
6 Department of Neurology, University Medicine Göttingen, Göttingen, Germany
7 Institute for Experimental Immunology and Imaging, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
8 Medical Proteom-Center Ruhr University, Bochum, Germany